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avoidance of radioactivity. We used both mostly as disease recur-
rence markers for adult patients with solid tumours, mainly breast
and colorectal cancers, believing, as others, that this reflects the
proliferative status of the particular tumour (Nekulova et al, 1995;
Van Dalen et al, 1998; Nisman et al, 1998). We have abandoned
the practice of monitoring patients with TPS (ASCO, 1997) after 7
months when we had completed 2703 tests. During this time we
observed isolated elevation of TPS higher than 140 U l–1, in 61
patients (breast and colorectal cancer), with other relevant markers
(CA15-3, CEA, CA19-9) being below cutoff. In only four of them
recurrence of disease was confirmed (breast cancer assessed by
CA15-3, CEA, imaging techniques and complete examination by a
medical oncologist). In two other patients (breast cancer) a suspect
finding appeared on bone gallium scan, which was not subse-
quently confirmed on CT scan. Another two patients presenting
with elevation of TPS were classified as stable disease (breast
cancer, local partial remission). In another 55 patients restaging
was performed at the discretion of a medical oncologist in charge,
however, without contributing new information.
Especially data on TPS elevations approaching up to 2600 U l–1
with no apparent disease progression in patients otherwise classi-
fied as ‘complete remission’ added significant stress to patients
and their doctors and generated substantial unnecessary testing.
Although inconclusive at this point, this group of false positives
suffered mostly from chronic inflammatory and/or noninflamma-
tory skin affections (herpetic infections, unhealed defects after
radiotherapy with or without secondary bacterial infections and in
some the reason was not apparent). In clinical practice the true
difference between ‘false positivity’ and ‘lead time’ is difficult to
distinguish during a limited time period; those markers with lead
times longer than 7 months do not prove very useful for influ-
encing patient outcome – this may obviously be the case of some
of our 55 patients. It is our belief that the validity of new
biomarkers and reevaluation of those used previously (Robertson,
1998) should be critically reassessed on a periodic basis if the
ultimate goal is to improve patient care while avoiding unneces-
sary increases in noise and cost of health care. In agreement with
the authors of the present paper, we currently recognize the poten-
tial of serum TPS only as a marker for monitoring response to
cytotoxic therapy in explicitly defined diagnostic groups and when
the potential of administering curative therapy exists, which
indeed may include neuroblastoma and Wilms’ tumor. In our
opinion, TPS should not be used as a diagnostic marker and only in
exceptional cases as a marker for disease recurrence.
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Sir,
We are glad that our paper (Rebhandl et al, 1998) has aroused the
interest of Drs Valik and Nekulova and that they can agree with
our conclusions regarding the potential of TPS as a tool for moni-
toring therapy response. However, we would like to make a few
comments on this letter.
First of all, our paper did not report clinical experience. The
situation in paediatric oncology is very different from adult
oncology. Apart from catecholamines and NSE in neuroblastoma
(not in Wilms’ tumor) there are no ‘established’ tumour-markers.
For TPS we actually had to establish normal values for healthy
children (Rebhandl et al, 1997) before addressing patients with
malignant disease. Furthermore, all our data are based on TPS and
not on TPA, which in our opinion is not comparable.
Breast and colorectal cancer are among the most frequent
malignant diseases in the western world, while the incidence of
DOI: 10.1054/ bjoc.1999.1245, available online at http://www.idealibrary.com on both neuroblastoma and Wilms’ tumour is fortunately low. Large
international multicentre studies are usually necessary to obtain
sufficient data within an acceptable period.
For these reasons it is quite difficult to compare the applicability
of TPS in so entirely different patient groups and different
malignancies.
Any tumour marker (and any diagnostic tool) must be weighed
against standard diagnostic procedures after exclusion of
confounding factors. Again, it is too early to judge whether TPS
measurements will become part of the diagnostic routine. In an
otherwise healthy child presenting with an abdominal mass it
could lead to an earlier diagnosis, especially since biopsy is strictly
forbidden in (suspected) Wilms’ tumours. ROC analysis enabled
us to show good differentiation between benign and malignant
disease in our patients.
The hypothesis that TPS could be a marker for apoptosis rather
than for proliferation is interesting but it still awaits final experi-
mental proof. TPS, which is a 22 kD fragment of cytokeratin 18
(Rydlander et al, 1996) may indeed correspond to the K18 C
fragment described by Caulin (1997). Direct testing with the
monoclonal antibody should decide this issue.
An activation of caspase-3 during chemo- or radiotherapy should
actually lead to an increase in TPS-serum values and not to the
significant decline we found in our patients. However, many issues
are still undecided in this area, among them the surprising phenom-
enon that elevated TPS can be found in non-epithelial tumours
(Vogl, 1995; Rebhandl, 1998. All this points to the fact that degra-
dation of cytokeratin 18 may be a key element of tumour biology.
With our study we also wanted to encourage further studies of
TPS and other tumour markers in paediatric malignancies.
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